Abstract: A system and method for defined aligning of an object. A first object with a first alignment is fed. The first alignment is detected and transmitted to a control device. The control device determines a first rotation angle on the basis of the first alignment and a predefined first alignment, and a speed profile of a first translational movement for a first rotor with a differential speed between the guiding device and the first rotor on the basis of the first rotation angle and a predefined speed of the guiding device. The control device controls the first rotor in the first translational movement along the aligning zone on the basis of the determined speed profile, and the first rotor, in interaction with the guiding device, turns the first object to the first predefined alignment in a first rotation about the first rotation angle on the basis of the differential speed.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: A system and method for defined aligning of an object. A first object with a first alignment is fed. The first alignment is detected and transmitted to a control device. The control device determines a first rotation angle on the basis of the first alignment and a predefined first alignment, and a speed profile of a first translational movement for a first rotor with a differential speed between the guiding device and the first rotor on the basis of the first rotation angle and a predefined speed of the guiding device. The control device controls the first rotor in the first translational movement along the aligning zone on the basis of the determined speed profile, and the first rotor, in interaction with the guiding device, turns the first object to the first predefined alignment in a first rotation about the first rotation angle on the basis of the differential speed.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: The present invention relates to a pharmaceutical formulation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of carbon atoms, wherein the fatty acid group comprises a carbon chain having 5 to 15 carbon atoms.

Abstract: An optical absorption spectrometry system includes first and second light sources, a dichroic beam combiner and a wavelength selective module. The first light source emits first light having first wavelengths within a first wavelength range, and the second light source emits second light having second wavelengths within a second wavelength range different from the first wavelength range. The dichroic beam combiner includes a predetermined first reflectance/transmission transition region, the dichroic beam combiner being configured to transmit a first portion of the first light and to reflect a second portion of the second light to provide combined light. The wavelength selective module is configured to disperse the combined light received at an entrance aperture, to select a sample wavelength range of the dispersed light as sample light, and to output the sample light having the selected sample wavelength range from an exit aperture for illuminating a sample.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: An optical absorption spectrometry system includes first and second light sources, a dichroic beam combiner and a wavelength selective module. The first light source emits first light having first wavelengths within a first wavelength range, and the second light source emits second light having second wavelengths within a second wavelength range different from the first wavelength range. The dichroic beam combiner includes a predetermined first reflectance/transmission transition region, the dichroic beam combiner being configured to transmit a first portion of the first light and to reflect a second portion of the second light to provide combined light. The wavelength selective module is configured to disperse the combined light received at an entrance aperture, to select a sample wavelength range of the dispersed light as sample light, and to output the sample light having the selected sample wavelength range from an exit aperture for illuminating a sample.

Abstract: An optical emission spectrometer system includes a light source and a dichroic beam combiner. The light source emits first light in a first direction and second light in a second direction different from the first direction. The dichroic beam combiner receives the first light via a first light path and the second light via a second light path, reflects a portion the first light into an entrance aperture of a light detection and measurement apparatus, and transmits a portion of the second light into the entrance aperture, enabling analysis and measurement of both first and second light characteristics simultaneously. The portion of the first light reflected into the entrance aperture predominately has wavelengths in a first range of wavelengths and the portion of the second light transmitted into the entrance aperture predominately has wavelengths in a second range of wavelengths, different from the first range of wavelengths.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: The present invention describes a balanced aqueous electrolyte solution. In particular, a balanced aqueous electrolyte solution that is particularly suitable as a solution for intravenous and subcutaneous infusion because of its being plasma-adapted is described. In addition to the balanced electrolyte solution itself, an electrolyte mixture as well as a process for preparing the balanced electrolyte solution from this mixture, and a medicament comprising the solution and optionally an active ingredient are provided.

Abstract: The present invention describes a balanced aqueous electrolyte solution. In particular, a balanced aqueous electrolyte solution that is particularly suitable as a solution for intravenous and subcutaneous infusion because of its being plasma-adapted is described. In addition to the balanced electrolyte solution itself, an electrolyte mixture as well as a process for preparing the balanced electrolyte solution from this mixture, and a medicament comprising the solution and optionally an active ingredient are provided.

Abstract: The present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of carbon atoms, wherein the fatty acid group comprises a carbon chain having 5 to 15 carbon atoms.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: A method and an arrangement for synchronizing a receiver for digital signals are described. The synchronizing information is derived from the center of distribution of the squared channel impulse response, which center of distribution is calculated directly from the sampling values of the channel frequency response. Thus a separate calculation of the channel impulse response via an inverse Fourier transform from the channel frequency response is unnecessary. The channel frequency response can be determined in a simple way by correlation of a received signal with a reference signal stored in memory in the receiver.

Abstract: A method is proposed that is used for frequency correction in multicarrier processes. A received signal is shifted by means of a predetermined frequency into the base band and then subjected to a modified Fourier transform. From the Fourier transformed signal, a measurement variable is ascertained that is proportional to the frequency deviation between the predetermined frequency and the frequency of the carrier signal. This measurement variable is taken into account in the Fourier transform and thus the frequency deviation is compensated for.